Resistance to AC220 in FLT3-ITD+ AML is mediated by a secondary FLT3-ITD F691L mutation

被引：0
|
作者：
Albers, C. [1 ]
Leischner, H. [1 ,2 ]
Verbeek, M. [1 ]
Yu, C. [1 ]
von Bubnoff, N. [1 ]
Peschel, C. [1 ]
Duyster, J. [1 ]
机构：
[1] III Med Dept, Munich, Germany
[2] HELIOS Klinikum Berlin Buch, Dept Hematol Oncol & Tumor Immunol, Berlin, Germany
来源：
ONKOLOGIE | 2012年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：117 / 117
页数：1
相关论文
共 50 条
  • [41] A combinatorial therapeutic approach to enhance FLT3-ITD AML treatment
    Long, Jun
    Chen, Xinjie
    Shen, Yan
    Lei, Yichen
    Mu, Lili
    Wang, Zhen
    Xiang, Rufang
    Gao, Wenhui
    Wang, Lining
    Wang, Ling
    Jiang, Jieling
    Zhang, Wenjun
    Lu, Huina
    Dong, Yan
    Ding, Yi
    Zhu, Honghu
    Hong, Dengli
    Sun, Yi Eve
    Hu, Jiong
    Liang, Aibin
    CELL REPORTS MEDICINE, 2023, 4 (11)
  • [42] Autophagy activation mediates resistance to FLT3 inhibitors in acute myeloid leukemia with FLT3-ITD mutation
    Dan Xu
    Yishan Chen
    Ying Yang
    Zhao Yin
    Changfen Huang
    Qiang Wang
    Ling Jiang
    Xuejie Jiang
    Changxin Yin
    Qifa Liu
    Guopan Yu
    Journal of Translational Medicine, 20
  • [43] Autophagy activation mediates resistance to FLT3 inhibitors in acute myeloid leukemia with FLT3-ITD mutation
    Xu, Dan
    Chen, Yishan
    Yang, Ying
    Yin, Zhao
    Huang, Changfen
    Wang, Qiang
    Jiang, Ling
    Jiang, Xuejie
    Yin, Changxin
    Liu, Qifa
    Yu, Guopan
    JOURNAL OF TRANSLATIONAL MEDICINE, 2022, 20 (01)
  • [44] Influence of IDH on FLT3-ITD status in newly diagnosed AML
    P Boddu
    K Takahashi
    N Pemmaraju
    N Daver
    C B Benton
    S Pierce
    M Konopleva
    F Ravandi
    J Cortes
    H Kantarjian
    C D DiNardo
    Leukemia, 2017, 31 : 2526 - 2529
  • [45] ASXL1-Mutated Donor HSCs Evolved into FLT3-ITD Positive AML in the Unrelated Donor and FLT3-ITD Negative AML in the Recipient after Transplant
    Liu, Zhongwen
    Liu, Hongxing
    Zhang, Yanli
    Kong, Dai
    Shi, Jie
    Zhang, Yin
    Wen, Meiying
    Song, Yongping
    Tong, Chunrong
    Chen, Mingyi
    Murphy, William J.
    Sun, Kai
    BLOOD, 2015, 126 (23)
  • [46] Efficacy and safety of quizartinib (AC220) in patients age ≥ 70 years with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia (AML).
    Perl, Alexander E.
    Dohner, Hartmut
    Rousselot, Philippe H.
    Marie, Jean-Pierre
    Martinelli, Giovanni
    Shah, Neil P.
    Levis, Mark J.
    Gammon, Guy
    Trone, Denise
    Cortes, Jorge E.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [47] Role of HDAC8 Upregulation in Resistance of FLT3-ITD AML Stem Cells to FLT3 Inhibitors
    Long, Jun
    Jia, Mingyuan
    Fang, Weiyue
    Chen, Xinjie
    Wang, Zhongyu
    Mu, Lili
    Xiang, Rufang
    Li, Jun-Min
    Hong, Dengli
    Liang, Aibin
    Hu, Jiong
    BLOOD, 2019, 134
  • [48] Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase
    Yang, Xiaochuan
    Sexauer, Amy
    Levis, Mark
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 164 (01) : 61 - 72
  • [49] Characterization of genomic alterations of cytarabine-resistant AML cells with FLT3-ITD mutation
    Yen, J. H.
    Chen, Z. A.
    Lin, L. I.
    Chen, P. Y.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2019, 27 : 1608 - 1608
  • [50] Secondary resistance to sorafenib in two patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations
    Scholl, Sebastian
    Spies-Weisshart, Baerbel
    Klink, Anne
    Muegge, Lars-Olof
    Fricke, Hans-Joerg
    Hochhaus, Andreas
    ANNALS OF HEMATOLOGY, 2011, 90 (04) : 473 - 475
12345